Venus Remedies Ltd (VENUSREM) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Part of MojoOne Strategy

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Venus Remedies

Kwality Pharma

NGL Fine Chem

Fermenta Biotec.

Sakar Healthcare

Syncom Formul.

Lincoln Pharma.

Hester Bios

Ind-Swift Labs.

Jagsonpal Pharma

Bajaj Healthcare

Why is Venus Remedies Ltd ?

Company has a low Debt to Equity ratio (avg) at 0 times

With a growth in Operating Profit of 96.37%, the company declared Very Positive results in Dec 25

The company has declared positive results for the last 5 consecutive quarters
ROCE(HY) Highest at 13.99%
INVENTORY TURNOVER RATIO(HY) Highest at 6.58 times
PBDIT(Q) Highest at Rs 37.52 cr.

With ROE of 10.5, it has a Fair valuation with a 1.8 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 167.50%, its profits have risen by 182.3% ; the PEG ratio of the company is 0.1

Increasing Participation by Institutional Investors

Institutional investors have increased their stake by 0.67% over the previous quarter and collectively hold 3.28% of the company
These investors have better capability and resources to analyse fundamentals of companies than most retail investors

Market Beating performance in long term as well as near term

Along with generating 167.50% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Venus Remedies should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Venus Remedies for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Venus Remedies

165.53%

3.10

53.38%

Sensex

5.37%

0.47

11.36%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.29%

EBIT Growth (5y)

29.54%

EBIT to Interest (avg)

37.06

Debt to EBITDA (avg)

0.63

Net Debt to Equity (avg)

-0.37

Sales to Capital Employed (avg)

1.15

Tax Ratio

26.34%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.28%

ROCE (avg)

7.85%

ROE (avg)

7.52%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.78

EV to EBIT

9.40

EV to EBITDA

7.43

EV to Capital Employed

2.25

EV to Sales

1.19

PEG Ratio

0.08

Dividend Yield

ROCE (Latest)

19.01%

ROE (Latest)

10.52%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

ROCE(HY)

Highest at 13.99%

INVENTORY TURNOVER RATIO(HY)

Highest at 6.58 times

PBDIT(Q)

Highest at Rs 37.52 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 20.81%

PBT LESS OI(Q)

Highest at Rs 30.95 cr.

PAT(Q)

Highest at Rs 25.58 cr.

EPS(Q)

Highest at Rs 19.13

-1What is not working for the Company

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 42.59 cr

Loading Valuation Snapshot...

Here's what is working for Venus Remedies

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 30.95 cr has Grown at 145.63%

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 25.58 cr has Grown at 116.9%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is very positive

PAT (Rs Cr)

Inventory Turnover Ratio- Half Yearly

Highest at 6.58 times and Grown

each half year in the last five half yearly periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Operating Profit (PBDIT) - Quarterly

Highest at Rs 37.52 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly

Highest at 20.81%

in the last five quarters

MOJO Watch

Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly

Highest at Rs 30.95 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

Highest at Rs 25.58 cr.

in the last five quarters

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly

Highest at Rs 19.13

in the last five quarters

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Venus Remedies

Cash and Cash Equivalents - Half Yearly

Lowest at Rs 42.59 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents